{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:53:04Z","timestamp":1784166784913,"version":"3.55.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015183","name":"Immunodiagnostic Systems Holdings","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015277","name":"Roche Products","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["ACF-2018-04-005"],"award-info":[{"award-number":["ACF-2018-04-005"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.bone.2020.115336","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T11:39:51Z","timestamp":1585395591000},"page":"115336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis"],"prefix":"10.1016","volume":"136","author":[{"given":"Andreas","family":"Fontalis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-3366","authenticated-orcid":false,"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2020.115336_bb0005","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/14656566.2019.1594772","article-title":"Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss","volume":"20","author":"Fontalis","year":"2019","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.bone.2020.115336_bb0010","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2018.1430764","article-title":"Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis","volume":"17","author":"Fontalis","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bone.2020.115336_bb0015","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.maturitas.2013.05.013","article-title":"Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013","volume":"75","author":"Compston","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2020.115336_bb0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0025-6196(11)61093-8","article-title":"Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis","volume":"82","author":"Kothawala","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bone.2020.115336_bb0025","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","article-title":"GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0035","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/EJE-17-0585","article-title":"Diagnosis of endocrine disease: bone turnover markers: are they clinically useful?","volume":"178","author":"Eastell","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2020.115336_bb0040","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0045","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","article-title":"Recommendations for the screening of adherence to oral bisphosphonates","volume":"28","author":"Diez-Perez","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0050","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bone.2020.115336_bb0055","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bone.2020.115336_bb0060","first-page":"S443","article-title":"Bisphosphonate affinity to hydroxyapatite and farnesyl pyrophosphate inhibitory potency, together, drive in vivo efficacy - ORA - Oxford University Research Archive","author":"Lundy","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0065","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115336_bb0070","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Heal"},{"key":"10.1016\/j.bone.2020.115336_bb0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bone.2020.115336_bb0085","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdl408","article-title":"Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis","volume":"18","author":"Aguiar Bujanda","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2020.115336_bb0090","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0025-6196(11)61093-8","article-title":"Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis","volume":"82","author":"Kothawala","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bone.2020.115336_bb0095","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00198-011-1796-6","article-title":"A reappraisal of generic bisphosphonates in osteoporosis","volume":"23","author":"Kanis","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0105","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00198-011-1850-4","article-title":"The association between automatic generic substitution and treatment persistence with oral bisphosphonates","volume":"23","author":"Str\u00f6m","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","article-title":"GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0115","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","article-title":"Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis","volume":"26","author":"Karlsson","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0120","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00198-015-3271-2","article-title":"Natural history, reasons for, and impact of low\/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study","volume":"27","author":"Clark","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11657-019-0593-2","article-title":"Adherence to bisphosphonates in the general population: a study in patients referred to a primary care service","volume":"14","author":"Donato","year":"2019","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bone.2020.115336_bb0130","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.clinthera.2019.05.001","article-title":"Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review","volume":"41","author":"Fardellone","year":"2019","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2020.115336_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027049","article-title":"Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review","volume":"9","author":"Fatoye","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.bone.2020.115336_bb0140","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/pds.2344","article-title":"Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway","volume":"21","author":"Devold","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bone.2020.115336_bb0145","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","article-title":"Compliance with drug therapy for postmenopausal osteoporosis","volume":"17","author":"Weycker","year":"2006","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0150","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2147\/PPA.S136890","article-title":"An upper and lower bound of the medication possession ratio","volume":"11","author":"Sperber","year":"2017","journal-title":"Patient Prefer. Adherence."},{"key":"10.1016\/j.bone.2020.115336_bb0155","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027049","article-title":"Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review","volume":"9","author":"Fatoye","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.bone.2020.115336_bb0165","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jbmr.342","article-title":"Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence","volume":"26","author":"Eastell","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0170","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bone.2020.115336_bb0175","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","article-title":"Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis","volume":"21","author":"Imaz","year":"2010","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2125.2008.03178.x","article-title":"Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women","volume":"66","author":"Blouin","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2020.115336_bb0185","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1185\/030079906X132370","article-title":"Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study","volume":"22","author":"van den Boogaard","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.bone.2020.115336_bb0190","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/jbmr.533","article-title":"Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence","volume":"27","author":"Sampalis","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"24","author":"Kanis","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0200","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1007\/s00198-013-2364-z","article-title":"Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group","volume":"24","author":"Hiligsmann","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0205","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a Meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0210","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00198-010-1372-5","article-title":"Adherence and profile of non-persistence in patients treated for osteoporosis\u2014a large-scale, long-term retrospective study in the Netherlands","volume":"22","author":"Netelenbos","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0215","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0220","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00198-011-1721-z","article-title":"Impact of bone turnover markers and\/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0225","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","article-title":"Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis","volume":"92","author":"Delmas","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115336_bb0230","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115336_bb0235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0197-2456(99)00054-9","article-title":"Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia","volume":"21","author":"De Amici","year":"2000","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.bone.2020.115336_bb0240","series-title":"Control. Clin. Trials","first-page":"S241","article-title":"Ethics in adherence promotion and monitoring","author":"Rand","year":"2000"},{"key":"10.1016\/j.bone.2020.115336_bb0245","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1378\/chest.118.2.290","article-title":"Unpredictability of deception in compliance with physician-prescribed bronchodilator inhaler use in a clinical trial","volume":"118","author":"Simmons","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.bone.2020.115336_bb0250","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-008-0660-9","article-title":"Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis","volume":"19","author":"Szulc","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0255","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0260","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1359\/jbmr.080703","article-title":"Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States","volume":"24","author":"Glover","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0265","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1359\/JBMR.041114","article-title":"Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling","volume":"20","author":"Riggs","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0270","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0275","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0280","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0285","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0290","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0295","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Fosamax actonel comparison trial investigators, treatment with once-weekly alendronate 70\u00a0mg compared with once-weekly risedronate 35\u00a0mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0300","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.clinthera.2009.04.018","article-title":"Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study","volume":"31","author":"Emkey","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2020.115336_bb0305","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/PL00004183","article-title":"Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy","volume":"11","author":"Fink","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0310","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1359\/jbmr.1998.13.7.1124","article-title":"Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability","volume":"13","author":"Hannon","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0315","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bone.2009.07.089","article-title":"A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy","volume":"45","author":"Rogers","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115336_bb0320","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bone.2007.01.016","article-title":"A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density","volume":"40","author":"Saag","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115336_bb0325","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0330","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/jbmr.2847","article-title":"Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis: secondary analysis of randomized controlled trial data","volume":"31","author":"Bell","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0335","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/8756-3282(95)00400-9","article-title":"Sustained response to intravenous alendronate in postmenopausal osteoporosis","volume":"17","author":"Vasikaran","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115336_bb0340","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jocd.2017.06.020","article-title":"Bone turnover markers: use in fracture prediction","volume":"20","author":"Vilaca","year":"2017","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2020.115336_bb0345","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/gme.0b013e31825ae17e","article-title":"Bone resorption and fracture across the menopausal transition","volume":"19","author":"Cauley","year":"2012","journal-title":"Menopause J. North Am. Menopause Soc."},{"key":"10.1016\/j.bone.2020.115336_bb0350","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1210\/jc.2015-4262","article-title":"Quantifying the balance between total bone formation and total bone resorption: an index of net bone formation","volume":"101","author":"Shieh","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115336_bb0355","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1359\/JBMR.0301244","article-title":"Biochemical markers of bone metabolism and prediction of fracture in elderly women","volume":"19","author":"Gerdhem","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0360","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bmj.312.7029.482","article-title":"Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study","volume":"312","author":"van Daele","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.bone.2020.115336_bb0365","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","article-title":"A meta-analysis of reference markers of bone turnover for prediction of fracture","volume":"94","author":"Johansson","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115336_bb0370","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1172\/JCI116387","article-title":"Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women","volume":"91","author":"Szulc","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2020.115336_bb0375","first-page":"719","article-title":"Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study","volume":"82","author":"Vergnaud","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115336_bb0380","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study","volume":"11","author":"Garnero","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0385","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0390","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1359\/jbmr.2000.15.12.2473","article-title":"Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin","volume":"15","author":"Luukinen","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0395","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jbmr.3355","article-title":"Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression","volume":"33","author":"Bauer","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0400","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial*","volume":"23","author":"Silverman","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0405","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00223-012-9629-y","article-title":"Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene","volume":"91","author":"Bruy\u00e8re","year":"2012","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115336_bb0410","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","author":"Eastell","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0415","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1359\/jbmr.07090b","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis","volume":"22","author":"Eastell","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0420","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s00198-016-3675-7","article-title":"Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study","volume":"27","author":"Marques","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-012-0392-y","article-title":"Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)","volume":"31","author":"Nishizawa","year":"2013","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2020.115336_bb0430","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cca.2016.06.036","article-title":"Clinical usefulness of bone turnover marker concentrations in osteoporosis","volume":"467","author":"Morris","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bone.2020.115336_bb0435","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cca.2016.06.036","article-title":"Clinical usefulness of bone turnover marker concentrations in osteoporosis","volume":"467","author":"Morris","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bone.2020.115336_bb0440","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.bone.2012.02.003","article-title":"Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study","volume":"50","author":"Eastell","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115336_bb0445","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5\u00a0mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","author":"Delmas","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0450","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1359\/jbmr.07090b","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis","volume":"22","author":"Eastell","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0455","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cca.2016.06.036","article-title":"Clinical usefulness of bone turnover marker concentrations in osteoporosis","volume":"467","author":"Morris","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bone.2020.115336_bb0460","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1359\/jbmr.07090b","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis","volume":"22","author":"Eastell","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0465","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","article-title":"Development of an algorithm for using PINP to monitor treatment of patients with teriparatide","volume":"22","author":"Eastell","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.bone.2020.115336_bb0470","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0475","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston","year":"2017","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bone.2020.115336_bb0480","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMc062792","article-title":"Prolonged bisphosphonate release after treatment in children","volume":"356","author":"Papapoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115336_bb0485","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2020.115336_bb0490","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/jbmr.1864","article-title":"BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate","volume":"28","author":"McNabb","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115336_bb0495","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00198-018-04823-5","article-title":"Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis","volume":"30","author":"Naylor","year":"2019","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0500","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","article-title":"International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis","volume":"49","author":"Vasikaran","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.bone.2020.115336_bb0505","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115336_bb0510","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jbmr.3654","article-title":"Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT extension I trials","volume":"34","author":"Kim","year":"2019","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:41:16Z","timestamp":1762659676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220301162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":102,"alternative-id":["S8756328220301162"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115336","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115336"}}